Neovacs S.A.

Research Neovacs S.A. (ALNEV) on Bullrun: market cap EUR 232.23K. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerALNEV
• ExchangePA
• CountryFrance
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 232.23K
• Financial periodFY2024
• RevenueEUR 366.35K
• Revenue growth-31.4%
• Net income-EUR 32.91M
• Free cash flow-EUR 3.68M
• Gross margin11.6%

Valuation Snapshot

latest market cap is EUR 232.23K.

About Neovacs S.A.

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies.

Frequently asked questions

What is Neovacs S.A.'s market cap?

Neovacs S.A.'s market capitalization is EUR 232.23K.

What does Neovacs S.A. do?

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology.